Does Highmark Blue Cross Blue Shield Cover Depression Treatment in Delaware? A 2026 Guide

Last updated: July 23, 2026

If you have Highmark Blue Cross Blue Shield coverage in Delaware and are seeking depression treatment, understanding your pharmacy benefits, prior authorization requirements, and state parity protections can help you navigate your options more effectively. This guide covers the Highmark BCBS Delaware depression formulary through Express Scripts (ESI), Delaware’s Electronic Prescribing of Controlled Substances (EPCS) requirements, and the appeal rights available to you under Delaware law.

Ready to connect with a licensed provider for depression treatment? Explore depression treatment options at Klarity Health and see if your plan may cover care.

Key Facts: Highmark BCBS Delaware. Depression Coverage (2026)

• Pharmacy Benefit Manager (PBM): Express Scripts (ESI)
• State parity law: Del. Code Ann. tit. 18, § 3343 (MHPAEA alignment. Mental health benefits must be at parity with medical/surgical benefits)
• DE EPCS: Standard antidepressants (SSRIs, SNRIs, NDRIs, atypicals, TCAs) are non-scheduled. EPCS entirely inapplicable. Spravato (esketamine nasal spray) = Schedule III = EPCS REQUIRED + REMS + TRD criteria.
• Highmark member services: 1-800-241-5704
• ESI pharmacy: 1-800-792-9558
• DE Insurance Commissioner: 1-302-674-7300

How Highmark BCBS Delaware Covers Depression Medications

Highmark Blue Cross Blue Shield of Delaware administers pharmacy benefits through Express Scripts (ESI). For depression treatment, the ESI formulary typically places generic first-line antidepressants on lower tiers with minimal prior authorization requirements. Brand-name medications and specialty agents often require prior authorization (PA), step therapy documentation, or both.

Coverage and tier placement may vary by specific plan, employer contract, and formulary year. Members should verify their current formulary at highmarkbcbs.com or by calling ESI directly at 1-800-792-9558.

ESI Formulary: Depression Medications (Typical 2026 Placement)

Tier placement and PA requirements may differ by plan. Verify your specific benefits at highmarkbcbs.com or by calling 1-800-241-5704 (Highmark member services) or 1-800-792-9558 (ESI pharmacy).

Delaware EPCS Requirements for Depression Medications

Delaware requires Electronic Prescribing of Controlled Substances (EPCS) for controlled substances under the Delaware Board of Medical Licensure and Discipline regulations (DE Admin Code, Title 24, § 1700). However, nearly all depression medications are non-scheduled and therefore fall entirely outside EPCS requirements.

DE EPCS Status by Depression Medication Category

The key takeaway: for the vast majority of depression treatment, EPCS is not a barrier. Providers prescribing standard antidepressants via telehealth in Delaware are not subject to EPCS requirements for those medications. Only Spravato triggers EPCS. And its REMS in-office administration requirement means telehealth prescribing is not applicable regardless of EPCS status.

Spravato (Esketamine): Special Considerations

Spravato is the only depression medication in Delaware that triggers both EPCS and additional clinical program requirements. Patients and providers should be aware of all three layers:

1. EPCS (Schedule III): Spravato must be prescribed electronically under Delaware’s EPCS requirement for controlled substances.
2. REMS Program: The FDA requires Spravato to be administered under a Risk Evaluation and Mitigation Strategy (REMS) program. It can only be dispensed to healthcare settings (not retail pharmacies), and patients must be monitored for at least two hours after each dose. Home administration is not permitted.
3. Treatment-Resistant Depression (TRD) Criteria: Under ESI’s PA criteria for Spravato, patients typically must have failed at least two adequate antidepressant trials at appropriate doses and durations. Documentation of prior treatment history is required for PA approval.

Because Spravato is administered in-office and requires REMS certification, telehealth providers do not prescribe it directly. If Spravato may be appropriate for your treatment plan, your Klarity provider can coordinate a referral to a REMS-certified in-office facility.

Prior Authorization for Depression Medications Under ESI

Most generic first-line antidepressants on ESI’s formulary do not require PA. The primary scenarios where prior authorization or step therapy documentation may be required are:

• Trintellix (vortioxetine): Step therapy typically requires documentation of at least one prior SSRI or SNRI trial at an adequate dose and duration before Trintellix will be approved.
• Auvelity (dextromethorphan/bupropion): PA is generally required. ESI may require documentation of 2 or more prior antidepressant trials, including at least one SSRI or SNRI. Clinical notes supporting the rationale for Auvelity over other agents strengthen the PA request.
• Spravato (esketamine): Specialty PA required. Documentation of 2+ failed adequate antidepressant trials is required to meet TRD criteria. REMS program enrollment for the administering facility is also required.
• Brand-name SSRIs/SNRIs: Brand versions of otherwise generic medications (e.g., brand Zoloft instead of sertraline) often require step therapy showing the generic was tried or is contraindicated.

How to Start the PA Process with Highmark/ESI

1. Confirm formulary tier: Call ESI at 1-800-792-9558 or log in at express-scripts.com to confirm the tier and PA requirements for your specific medication.
2. Obtain a PA form: Your provider can download ESI PA forms from the ESI provider portal or call 1-800-792-9558 for fax submissions.
3. Gather clinical documentation: Prior treatment history, diagnosis codes, duration of prior trials, and the clinical rationale for the requested medication.
4. Submit and track: ESI typically processes non-urgent PA requests within 3 business days and urgent requests within 24 hours. Your provider will receive a written determination.
5. Request a peer-to-peer review: If the initial PA is denied, your provider can request a peer-to-peer call with the ESI medical reviewer before filing a formal appeal.

Delaware Parity Protections Under § 3343

Delaware’s mental health parity law. Del. Code Ann. tit. 18, § 3343. Aligns with the federal Mental Health Parity and Addiction Equity Act (MHPAEA). Under this law, fully-insured health plans regulated by Delaware are required to:

• Cover mental health and substance use disorder (MH/SUD) benefits at parity with medical and surgical benefits of the same classification
• Apply financial requirements (copays, coinsurance) and treatment limitations (quantity limits, step therapy) for MH/SUD benefits no more restrictively than those applied to medical/surgical benefits
• Make their non-quantitative treatment limitation (NQTL) analyses available to members and the Delaware Department of Insurance (DOI) upon request

If you believe Highmark BCBS is applying more restrictive PA requirements or step therapy for your depression medication than it applies to comparable medical conditions, this may constitute a parity violation. You have the right to request the insurer’s NQTL analysis and to file a complaint with the Delaware DOI.

Note: § 3343 applies to fully-insured commercial plans regulated by Delaware. Self-funded employer plans (ERISA plans) are governed by federal MHPAEA rather than state parity law. For ERISA plan parity complaints, contact the Department of Labor’s Employee Benefits Security Administration (EBSA) at 1-866-444-3272.

How to Appeal a Depression Treatment Denial

If Highmark BCBS denies coverage for a depression medication or treatment, you have the right to appeal at multiple levels:

1. Internal appeal: File a formal appeal with Highmark BCBS within the timeframe specified in your denial letter (typically 180 days). Provide your provider’s clinical documentation, prior treatment history, and any peer-reviewed evidence supporting the requested medication. Call Highmark member services at 1-800-241-5704 for instructions.
2. Peer-to-peer review: Your prescribing provider can request a physician-to-physician call with Highmark’s medical reviewer. This step often resolves denials before a formal external review is needed.
3. External review: If the internal appeal is upheld, you may request an independent external review through the Delaware Department of Insurance (1-302-674-7300). For fully-insured plans, Delaware DOI assigns an Independent Review Organization (IRO) to conduct the review at no cost to you.
4. Parity complaint: If the denial reflects an MH/SUD parity violation under § 3343, you may file a separate parity complaint with the Delaware DOI alongside your external review request. For ERISA plans, file a parity complaint with DOL EBSA at 1-866-444-3272.
5. State Insurance Commissioner: Contact the Delaware Department of Insurance directly at 1-302-674-7300 for guidance on your consumer rights and appeal options.

Depression Treatment at Klarity Health

Klarity Health connects patients with licensed providers across Delaware who specialize in depression treatment, including medication management and therapy coordination. Our network of 2,000+ licensed providers can evaluate your symptoms, review your treatment history, and prescribe first-line antidepressants where clinically appropriate. Often within days of your first appointment.

Klarity providers are familiar with prior authorization documentation requirements for ESI and Highmark BCBS plans. When a PA is needed for a brand-name medication or a novel agent like Auvelity, your Klarity provider can support the documentation process.

See if your Highmark plan may cover depression treatment through Klarity Health.

Frequently Asked Questions

Does Highmark BCBS Delaware cover antidepressants?

Most generic antidepressants (SSRIs, SNRIs, bupropion, mirtazapine) are typically covered on ESI’s formulary at Tier 1. 2 with no prior authorization required. Brand-name and newer agents may require step therapy or PA. Verify your specific plan’s coverage by calling ESI at 1-800-792-9558.

Does Highmark BCBS cover Spravato (esketamine) in Delaware?

Spravato may be covered under specialty pharmacy benefits through ESI, but it typically requires specialty PA, documentation of treatment-resistant depression (2+ failed adequate antidepressant trials), and enrollment in the REMS program. Spravato must be administered in a REMS-certified healthcare setting. It is not available for home use or via standard telehealth.

Do I need a controlled substance prescription (EPCS) for my antidepressant in Delaware?

No. Virtually all standard antidepressants. SSRIs, SNRIs, bupropion, mirtazapine, TCAs, Trintellix, and Auvelity. Are non-scheduled and are not subject to Delaware’s EPCS requirement. Only Spravato (esketamine, Schedule III) triggers EPCS, and it is administered in-office rather than dispensed to patients.

What is the Highmark step therapy requirement for Trintellix?

ESI’s formulary for Trintellix (vortioxetine) typically requires documentation of at least one prior SSRI or SNRI trial at an adequate dose and duration. If a prior SSRI or SNRI was medically contraindicated or caused a significant adverse reaction, your provider may be able to request a step therapy exception with appropriate documentation.

Can I appeal a PA denial for my depression medication?

Yes. You have the right to an internal appeal with Highmark BCBS, a peer-to-peer review between your provider and Highmark’s medical reviewer, and an independent external review through the Delaware Department of Insurance. If the denial implicates mental health parity rights, you may also file a complaint under § 3343.

Does Delaware’s mental health parity law apply to my Highmark plan?

Del. Code Ann. tit. 18, § 3343 applies to fully-insured commercial plans regulated by Delaware. If your coverage comes through a self-funded employer plan, federal MHPAEA applies instead. Contact Highmark at 1-800-241-5704 to confirm whether your plan is fully-insured or self-funded.

Key Contacts

• Highmark BCBS DE Member Services: 1-800-241-5704
• Express Scripts (ESI) Pharmacy: 1-800-792-9558
• Delaware Department of Insurance: 1-302-674-7300 | insurance.delaware.gov
• DOL EBSA (ERISA/federal parity): 1-866-444-3272

Disclaimer: This guide is for informational purposes only and does not constitute legal, medical, or insurance advice. Coverage, formulary placement, tier assignments, and prior authorization requirements vary by plan, employer contract, and formulary year. Always verify your specific benefits with Highmark BCBS or ESI before scheduling care or filling a prescription. Klarity Health does not guarantee insurance coverage for any specific treatment or medication.